← Back to all trials
Active Not Recruiting
NCT06496620
A Study to Evaluate Solrikitug in Participants With COPD (ZION)
Conditions: COPD
Sex: All
Ages: 40 Years – 75 Years
Healthy volunteers: No
Phase: PHASE2
Enrollment: 182
Sponsor: Uniquity One (UNI)
Location: University of Alabama at Birmingham Hospital Birmingham Alabama
Summary
A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants with Chronic Obstructive Pulmonary Disease (COPD).
Eligibility Criteria
Inclusion Criteria:
* At least 40 years of age and no older than 75 years.
* Documented diagnosis of COPD for at least 12 months prior to Screening, defined by the GOLD Guidelines (2023), and elevated blood eosinophils at screening.
* At Screening FEV1/FVC ratio must be \
Source: ClinicalTrials.gov (NCT06496620). StuddyBuddy aggregates publicly available trial information.
